Zhitong Finance App News, Federal Pharmaceuticals (03933.HK) announced that UBT251 injection, a Class 1 innovative drug independently developed by the company's wholly-owned subsidiary Federal Biotechnology (Zhuhai Hengqin) Co., Ltd. (Federal Biotechnology), has completed administration to participants in the first phase III clinical study of overweight/obesity in China.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Federal Pharmaceuticals (03933.HK) announced that UBT251 injection, a Class 1 innovative drug independently developed by the company's wholly-owned subsidiary Federal Biotechnology (Zhuhai Hengqin) Co., Ltd. (Federal Biotechnology), has completed administration to participants in the first phase III clinical study of overweight/obesity in China.